RE:Topline dataRepoirting in both Canada and US that hospitalization is up, ICU's are jammed...with variants and third waves happening at the same time as vaccinations, think there is still a significant play for AGN within this direction. The IB shot themselves in the foot with the immeiate downgrade, think they are shaking the tree a bit to free up some cheap shares. Time will tell..along with what will be the next phase of discusions with the FDA - Emergency use.
Not to mention that lung scaring hasn't been accounted for as of yet, wich would probably be within their next stage of discussions with the FDA.
Agree that management should defintely augment their team with some heavy hitters to realize the potential. As for the Canadian landscape, as announced today, money will immediately be hitting what they think would make the biggest media splash - vaccine manufacturing in this country....